Literature DB >> 10771473

Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy.

D Cho1, T G Kim, W Lee, Y I Hwang, H I Cho, H Han, O Kwon, D Kim, H Park, D Houh.   

Abstract

Interleukin-18 has been described recently as a cytokine secreted primarily by Kupffer cells. Furthermore, it has been shown that it has significant anti-tumor effects, which are mediated by T cells and natural killer cells, in a manner similar to interleukin-12. Here, we report the evaluation of the effects of the systemic administration of interleukin-18 in combination with B7-1 (CD80) expressed on tumor cells [interleukin-18 + B7-1] on the growth of murine B16 melanoma in vivo. After the subcutaneous inoculation of B16 melanoma, B16 tumors grew progressively in immunocompetent syngeneic C57BL/6 mice. Mice treated with either interleukin-18 or immunized with B7-1-transduced B16 did not demonstrate significant anti-tumor effect. The combination of the two treatments, however, resulted in dramatic suppression of melanoma formation, tumor growth, and a significant improvement in survival. Inhibitory effects of [interleukin-18 + B7-1] on lung metastasis in mice were also detected. Additionally, mice treated with [interleukin-18 + B7-1] showed an increase of natural killer cytotoxicity and interferon-gamma production in vivo. Unlike [interleukin-18 + B7-1], [interleukin-12 + B7-1] did not have a strong anti-tumor effect against B16 melanoma. Histologic characterization after the [interleukin-18 + B7-1] treatment confirmed the infiltration of natural killer cells into the tumor, suggesting that natural killer cells may be involved in the [interleukin-18 + B7-1]-induced anti-tumor effect. This finding was confirmed by showing that depletion of NK1.1+ cells before immunization inhibits the [interleukin-18 + B7-1]-induced anti-tumor effect. Depletion of CD3+ cells in vivo also decreased the anti-tumor effect of [interleukin-18 + B7-1], suggesting the importance of CD3+ T cells. Collectively, combination with interleukin-18 and B7-1 expression has synergistic anti-tumor effects against B16 murine melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10771473     DOI: 10.1038/sj.jid.5600685

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein.

Authors:  S H Kim; T Azam; D Y Yoon; L L Reznikov; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  The -137G>C polymorphism in interleukin-18 promoter region and cancer risk: evidence from a meta-analysis of 21 studies.

Authors:  Tie-Jun Liang; Hui Ma; Cong-Xiao Wang; Yin-Rong Liu; Xing-Guo Wang
Journal:  Tumour Biol       Date:  2013-06-22

3.  AIM2 inflammasome mediates Arsenic-induced secretion of IL-1 β and IL-18.

Authors:  Mingfang Zhang; Yuanlin Qi; Hui Li; Jiajun Cui; Lu Dai; Jacqueline A Frank; Jian Chen; Wenhua Xu; Gang Chen
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 8.110

4.  Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components.

Authors:  Rongrong Liu; Agnieszka D Truax; Liang Chen; Peizhen Hu; Zengshan Li; Jun Chen; Chaojun Song; Lihua Chen; Jenny Pan-Yun Ting
Journal:  Oncotarget       Date:  2015-10-20

Review 5.  The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.

Authors:  Sourav Paul; Girdhari Lal
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

Review 6.  Interleukin-18 in Inflammatory Kidney Disease.

Authors:  Yasuaki Hirooka; Yuji Nozaki
Journal:  Front Med (Lausanne)       Date:  2021-03-01

7.  Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease.

Authors:  Loris R Lopetuso; Saleem Chowdhry; Theresa T Pizarro
Journal:  Front Immunol       Date:  2013-07-09       Impact factor: 7.561

Review 8.  Beneficial and Detrimental Roles of NLRs in Carcinogenesis.

Authors:  Ann M Janowski; Ryan Kolb; Weizhou Zhang; Fayyaz S Sutterwala
Journal:  Front Immunol       Date:  2013-11-12       Impact factor: 7.561

Review 9.  RNA-electroporated T cells for cancer immunotherapy.

Authors:  Fernanda Pohl-Guimarães; Lan B Hoang-Minh; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2020-10-07       Impact factor: 8.110

10.  Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal.

Authors:  Ayesha Rahman; Lingadahalli S Shashidhara
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.